We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AnaptysBio Inc | NASDAQ:ANAB | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.63 | 8.64% | 20.50 | 21.00 | 92.00 | 21.61 | 18.715 | 18.92 | 649,412 | 00:56:59 |
From Apr 2019 to Apr 2024
By Adriano Marchese
AnaptysBio Inc. said Thursday that the U.S. Food and Drug Administration approved GlaxoSmithKline PLC's biologics license application for JEMPERLI, a treatment for endometrial cancer.
The clinical-stage biotechnology company said JEMPERLI, also known as dostarlimab-gxly, was generated by AnaptysBio and developed by TESARO Inc.--now a part of GSK--under a collaboration agreement.
AnaptysBio received a $20 million milestone payment as part of the approval.
A Biologics License Application for JEMPERLI--a treatment for patients with mismatch repair deficient recurrent or advanced endometrial cancer--is needed to obtain permission for distribution across U.S. states.
"This event provides important validation for our proprietary SHM antibody discovery platform and provides significant potential future milestone and royalty revenue to support AnaptysBio's growth," President and Chief Executive Hamza Suria said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
April 22, 2021 17:04 ET (21:04 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year AnaptysBio Chart |
1 Month AnaptysBio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
